Abstract：Objective：To analyze the main active components and potential mechanisms of Tuomin Decoction in treating allergic rhinitis（AR）using network pharmacology and molecular docking technology. Methods： The active components and protein targets of each herb in Tuomin Decoction were collected using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP） and converted into gene targets via the UniProt database. AR-related targets were obtained from the GeneCards and OMIM databases. The intersection genes between Tuomin Decoction and AR were identified，and a drug-component-target network was constructed and analyzed using Cytoscape software to screen core targets and active components. Protein-protein interaction（PPI） networks were obtained from the STRING database and Cytoscape software for drawing and conducting network topology analysis. Gene Ontology（GO）and Kyoto Encyclopedia of Genes and Genomes（KEGG）analyses were performed on the intersection targets using the DAVID database to identify significant biological processes and signaling pathways， and a targetsignaling pathway network was constructed. Molecular docking of key chemical components and target molecules was conducted using AutoDockTools software. Results： A total of 41 active components of Tuomin Decoction were identified，involving 98 targets，with 2 371 AR targets and 47 intersection targets. Quercetin，luteolin，β-sitosterol， xyloidone，and acacetin were the top five active compounds for treating AR. Key targets included interleukin-6（IL-6）， B-cell lymphoma-2（BCL-2），and cysteine-aspartic acid protease-3（CASP-3）. GO enrichment analysis showed that the biological processes of Tuomin Decoction in treating AR were mainly focused on epithelial cell proliferation， response to bacterial-derived molecules，and response to hypoxia. The nuclear membrane，membrane rafts，membrane microdomains， and vesicle lumen were identified as key cellular components. Molecular functions primarily involved DNA-binding transcription factor binding， RNA polymerase 2-specific DNA-binding transcription factor binding， ubiquitin protein ligase binding， and ubiquitin-like protein ligase binding. KEGG pathway analysis highlighted the advanced glycation end products-receptor for advanced glycation end products （AGE-RAGE） signaling pathway， hypoxia-inducible factor-1α（HIF-1α）signaling pathway， and phosphoinositide 3-kinase-protein kinase B（PI3KAKT） signaling pathway as key pathways. Molecular docking results indicated that the active components quercetin and luteolin in Tuomin Decoction have strong binding affinity for key targets IL-6 and BCL-2. Conclusion： Tuomin Decoction may treat AR by acting on targets such as IL-6 and BCL-2 through active components like quercetin and luteolin， and by regulating pathways such as AGE-RAGE， HIF-1α， and PI3K-AKT to inhibit inflammatory responses，reduce oxidative stress，and modulate cell proliferation and apoptosis.